Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

C4 Therapeutics, Inc. - Common Stock (NQ:CCCC)

2.368 -0.062 (-2.57%)
Streaming Delayed Price Updated: 12:49 PM EST, Dec 16, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about C4 Therapeutics, Inc. - Common Stock

< Previous 1 2 3 Next >
C4 Therapeutics Inc. (NASDAQ: CCCC) Highlighted for Surprising Price Action
Via Investor Brand Network
News headline image
C4 Therapeutics and Betta Pharmaceuticals Announce Exclusive Licensing Agreement for the Development and Commercialization in Greater China of CFT8919, an Orally Bioavailable BiDAC™ Degrader of EGFR L858R for NSCLC
From C4 Therapeutics, Inc.
Via GlobeNewswire
News headline image
C4 Therapeutics Reports First Quarter 2023 Financial Results and Recent Business Highlights
From C4 Therapeutics, Inc.
Via GlobeNewswire
News headline image
C4 Therapeutics to Participate in the Stifel 2023 Virtual Targeted Oncology Days
From C4 Therapeutics, Inc.
Via GlobeNewswire
News headline image
C4 Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Business Highlights
From C4 Therapeutics, Inc.
Via GlobeNewswire
News headline image
C4 Therapeutics to Present at Two Virtual February 2023 Conferences
From C4 Therapeutics, Inc.
Via GlobeNewswire
News headline image
C4 Therapeutics Announces First Patient Dosed in Phase 1/2 Clinical Trial Evaluating CFT1946, an Orally Bioavailable BiDAC™ Degrader, in BRAF V600 Mutant Solid Tumors
From C4 Therapeutics, Inc.
Via GlobeNewswire
News headline image
C4 Therapeutics Announces 2023 Strategic Priorities to Advance Portfolio of Targeted Protein Degradation Medicines
From C4 Therapeutics, Inc.
Via GlobeNewswire
News headline image
C4 Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference
From C4 Therapeutics, Inc.
Via GlobeNewswire
News headline image
C4 Therapeutics Reports Third Quarter 2022 Financial Results and Recent Business Highlights
From C4 Therapeutics, Inc.
Via GlobeNewswire
News headline image
C4 Therapeutics Receives Study May Proceed Letter from U.S. FDA to Initiate Phase 1/2 Clinical Trial of CFT1946, an Orally Bioavailable BiDAC™ Degrader, in BRAF-V600 Mutant Solid Cancers
Phase 1/2 Clinical Trial Will Study CFT1946 in BRAF-V600 Mutant Solid Cancers Including Lung, Colorectal and Melanoma; Trial Initiation Expected by Year End 2022 
From C4 Therapeutics, Inc.
Via GlobeNewswire
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.